CLOSEOUT LETTER
Stason Pharmaceuticals, Inc. MARCS-CMS 604889 —
- Delivery Method:
- Via Email Delivery Confirmation
- Product:
- Drugs
- Recipient:
-
Recipient NameHarry T. Fan
-
Recipient TitleChief Executive Officer
- Stason Pharmaceuticals, Inc.
11 Morgan
Irvine, CA 92618
United States
- Issuing Office:
- Division of Pharmaceutical Quality Operations IV
United States
- 949-608-2900
Dear Mr. Fan:
The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter [CMS #604889 and dated July 8, 2020]. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV